Search
Surrozen Inc
SRZNAdd to Watchlist
23.960USD
+0.230+0.97%
Close 08-14 16:00（ET）Quotes delayed by 15 min
281.62MMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-14The current earnings forecast score of Surrozen Inc is 8.40, ranking 131 out of 387 in the Biotechnology & Medical Research industry. The average price target is 37.00, with a high of 42.00 and a low of 32.00.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
43.000
Target Price
+79.47%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Surrozen Inc
SRZN
5
Beigene Ltd
ONC
28
argenx SE
ARGX
28
Ionis Pharmaceuticals Inc
IONS
25
IQVIA Holdings Inc
IQV
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Surrozen Inc's expected revenue for the next quarter?
Surrozen Inc's expected revenue is 467.25K.
What is Surrozen Inc's price target?
Analysts forecast that Surrozen Inc's price target is USD 37.00, with the highest forecast at USD 42.00 and the lowest forecast at USD 32.00.
How have Surrozen IncSRZN's recent earnings per share performed?
The market expectation was USD 4.30, while Surrozen IncSRZN's earnings per share (EPS) for the previous quarter was USD -11.65. EPS for the next quarter is expected at USD -1.04.
What is the analyst rating for Surrozen Inc?
Based on the ratings of Surrozen Inc's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.